ArticleACS medicinal chemistry letters2020

Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.

Andrew E Shouksmith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.